How to Inject ARA-290: Sites, Syringes and Steps
Where to inject ARA-290, which syringe to use, how to read units and the hygiene steps that prevent infection.
Injection sites
Most peptides are injected under the skin (subcutaneously), into the fatty layer rather than the muscle.
- Belly: at least 2 inches (5 cm) away from the navel.
- Front and outer thighs.
- Back of the upper arms, if someone else can reach it.
- Rotate sites each time and avoid skin that is bruised, scarred or irritated.
Syringe and needle
U-100 insulin syringes are marked in units: 100 units equal 1 mL, so 10 units is 0.1 mL. They come in 0.3, 0.5 and 1 mL sizes; a smaller syringe has finer marks and is easier to read for small doses. Needle length and gauge used for ARA-290 in studies: not reported in study abstracts (PubMed search, 11 Oct 2026).
How to read an insulin syringeStep by step
- 1Wash your handsUse soap and water, and work on a clean surface.
- 2Check the vialLabel, lot and date present; solution clear with no particles. Mixing a powder vial first? Use sterile bacteriostatic water.
- 3Clean the vial top and the siteWipe both with an alcohol swab and let them dry.
- 4Draw the dosePull the plunger to the units mark for your dose, then tap out air bubbles and re-check the mark.
- 5InjectPinch a fold of skin, insert the needle at 45 to 90 degrees, push the plunger slowly and wait a few seconds before withdrawing.
- 6Dispose safelyPut the used syringe straight into a sharps container. Never reuse or share needles.
The routes and schedules used in published studies
In the type 2 diabetes phase 2 trial, participants self-administered ARA 290 4 mg subcutaneously once a day for 28 days.[8]
In the diabetic macular edema trial, participants self-administered cibinetide 4 mg/day subcutaneously for 12 weeks.[9]
The sarcoidosis pilot gave ARA 290 2 mg intravenously three times a week for 4 weeks instead of under the skin.[10]
Animal route
In diabetic mice, cibinetide 30 micrograms per kilogram was given under the skin daily; this is a mouse dose and is not converted to a human amount.[11]
Common questions
Where do you inject ARA-290?
Under-the-skin (subcutaneous) injections are usually given in the belly, at least 2 inches from the navel, the front of the thighs or the back of the upper arms. Rotate sites each time.
What syringe is used for ARA-290?
Vials are usually drawn with a U-100 insulin syringe, where 100 units equal 1 mL. Common sizes hold 0.3, 0.5 or 1 mL. Match the syringe to the dose so the mark is easy to read.
How often is ARA-290 injected?
The interval comes from the study or prescription, not from this guide. See the dosage page for what studies used.
Where was ARA 290 injected in studies?
The cached trial abstracts state the route (subcutaneous or intravenous) but do not name an injection site; this page does not give technique instructions.[8]
More on ARA-290
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3PubMed search: (ARA-290[tiab] OR ARA290[tiab] OR cibinetide[tiab]) (75 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 4PubMed search: (ARA-290[tiab] OR ARA290[tiab] OR cibinetide[tiab]) AND (sarcoidosis[tiab] OR neuropath*[tiab] OR patients[tiab] OR randomized[tiab]) (29 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: (ARA-290[tiab] OR ARA290[tiab] OR cibinetide[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: (ARA-290[tiab] OR ARA290[tiab] OR cibinetide[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (22 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 7PubMed search: (ARA-290[tiab] OR ARA290[tiab] OR cibinetide[tiab] OR pHBSP[tiab]) AND (patients[tiab] OR subjects[tiab] OR volunteers[tiab]) (18 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 8ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.Molecular medicine (Cambridge, Mass.) · 2015PMID 25387363Accessed 2 Oct 2026
- 9A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.Journal of clinical medicine · 2020PMID 32674280Accessed 2 Oct 2026
- 10Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.Molecular medicine (Cambridge, Mass.) · 2012PMID 23168581Accessed 2 Oct 2026
- 11Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes.Biochimica et biophysica acta. Molecular basis of disease · 2018PMID 29223734Accessed 2 Oct 2026
Found an error? Report a correction.